Search

Your search keyword '"Pol Stanislas"' showing total 135 results

Search Constraints

Start Over You searched for: Author "Pol Stanislas" Remove constraint Author: "Pol Stanislas" Database Journals@OVID Remove constraint Database: Journals@OVID
135 results on '"Pol Stanislas"'

Search Results

1. Tenofovir Versus Placebo to Prevent Perinatal Transmission of Hepatitis B

3. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B

5. The HepHIV 2017 Conference in Malta: joining forces for the earlier diagnosis of HIV and viral hepatitis

6. Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

8. Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis

11. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)

20. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)

23. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

24. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

25. Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

27. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study

30. Efficacy and safety of MK-5172 + MK-8742 ± ribavirin in HCV mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrhotic patients with hepatitis C virus genotype 1 infection: The C-WORTHY study (Final results, Parts A and B): 236

31. An Integrated Safety and Efficacy Analysis of >500 Patients with Compensated Cirrhosis Treated with Ledip-asvir/Sofosbuvir with or without Ribavirin: 82

33. All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection

35. Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients

38. Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial

46. Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: posthoc analysis of the REALIZE Phase III study

49. Interim report on efficacy results of a new sustained release interferon-alpha-2b (IFNα-2bXL) compared with Pegylated IFN-alpha-2b during a 3-month course of combined therapy with ribavirin in hepatitis C patients (Phase 2 study: ANRS HC23 COAT-IFN): 1761

Catalog

Books, media, physical & digital resources